본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

AntibodySystem

[Antibodysystem] Research Grade Coltuximab

Cat-No. DHD10801




AntibodySystem는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다. 





제품 설명 


Research Grade Coltuximab




제품 번호


DHD10801




제품 특징

Description

Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.

Catalog No.

DHD10801

Host species

Chimeric

Species reactivity

Human

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

1 mg/ml

Purity

>95% by SDS-PAGE.

Clonality

Monoclonal

Isotype

IgG1-kappa

Applications

Research Grade Biosimilar

Target

CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

XtenCHO

Accession

P15391

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

CD19, SAR3419, CAS: 1269764-99-9

Note

For research use only. Not suitable for clinical or therapeutic use.




Data Image


  • SDS-PAGE
    SDS PAGE for Coltuximab Ravtansine
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-MALS.

                                        



AntibodySystem의 모든 제품들을 만나 보세요!  


Products

Recombinant Protein

Antibody

Assay Kit

Research Biosimilar